A recent U.S. study revealed that approximately 15.5 million American adults are living with attention-deficit hyperactivity disorder (ADHD), yet many face challenges in accessing appropriate treatment. According to the findings published in the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report, only around one-third of adults diagnosed with ADHD received a prescription for stimulant medication in the previous year.
Moreover, a significant obstacle for those with prescriptions was the difficulty in filling them due to medication shortages. This issue was reported by nearly three-quarters of individuals prescribed stimulant drugs like the commonly used amphetamine (Adderall) for ADHD management.
Despite the prevalence of ADHD symptoms worldwide, affecting roughly 2% to 5% of adults with characteristics like inattention, hyperactivity, and impulsivity, access to adequate treatment remains a concern. The study, the first of its kind since 2003, highlighted the gap in care for those diagnosed with ADHD, especially in receiving necessary medications.
The onset of ADHD symptoms typically occurs in childhood, yet the survey revealed that 55% of adults with the condition received their diagnosis later in life. The COVID-19 pandemic saw an increase in prescriptions for ADHD medications, but shortages exacerbated the challenges faced by patients in need of these treatments.
In response to the pandemic, expanded telehealth services have played a crucial role in facilitating ADHD diagnosis and treatment. Nearly half of the participants in the study utilized telemedicine for managing their ADHD, including obtaining medication prescriptions remotely.
The researchers emphasized the potential benefits of telehealth in addressing the needs of individuals with ADHD, suggesting that it could improve access to behavioral therapies alongside medication management. Despite the promising role of telemedicine, further research is needed to evaluate its effectiveness and safety in treating ADHD.
The data, based on a rapid survey conducted by the National Center for Health Statistics among 7,046 U.S. adults aged 18 and older in October–November 2023, sheds light on the existing barriers to ADHD treatment and underscores the importance of addressing these challenges to enhance care for individuals with ADHD.